313 related articles for article (PubMed ID: 10381115)
1. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.
Cuenca-Estrella M; Ruiz-Díez B; Martínez-Suárez JV; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 1999 Jan; 43(1):149-51. PubMed ID: 10381115
[TBL] [Abstract][Full Text] [Related]
2. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Gilgado F; Serena C; Cano J; Gené J; Guarro J
Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.
Zeng J; Kamei K; Zheng Y; Nishimura K
Nihon Ishinkin Gakkai Zasshi; 2004; 45(2):101-4. PubMed ID: 15118667
[TBL] [Abstract][Full Text] [Related]
4. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
Lackner M; de Hoog GS; Verweij PE; Najafzadeh MJ; Curfs-Breuker I; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 May; 56(5):2635-42. PubMed ID: 22290955
[TBL] [Abstract][Full Text] [Related]
5. Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
Shah KB; Wu TG; Wilhelmus KR; Jones DB
Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of four novel triazoles against Scedosporium spp.
Carrillo AJ; Guarro J
Antimicrob Agents Chemother; 2001 Jul; 45(7):2151-3. PubMed ID: 11408242
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
Lewis RE; Wiederhold NP; Klepser ME
Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
[TBL] [Abstract][Full Text] [Related]
8. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.
Gil-Lamaignere C; Roilides E; Mosquera J; Maloukou A; Walsh TJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2234-7. PubMed ID: 12069979
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
10. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
[TBL] [Abstract][Full Text] [Related]
11. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
[TBL] [Abstract][Full Text] [Related]
12. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
Radford SA; Johnson EM; Warnock DW
Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
[TBL] [Abstract][Full Text] [Related]
15. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
Wiederhold NP; Law D; Birch M
J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
Espinel-Ingroff A; Boyle K; Sheehan DJ
Mycopathologia; 2001; 150(3):101-15. PubMed ID: 11469757
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
Nguyen MH; Yu CY
J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of conventional antifungal agents against Scedosporium apiospermum isolates recovered from clinical and environmental samples in Nigeria.
Nweze EI; Okafor JI
Acta Microbiol Immunol Hung; 2010 Sep; 57(3):209-14. PubMed ID: 20870592
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
20. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.
Berenguer J; Rodríguez-Tudela JL; Richard C; Alvarez M; Sanz MA; Gaztelurrutia L; Ayats J; Martinez-Suarez JV
Medicine (Baltimore); 1997 Jul; 76(4):256-65. PubMed ID: 9279332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]